Junhui Sun

Junhui Sun

Auto-generated profile, based on publicly available information

Junhui Sun

Reproductive Medicine Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SHShuai Han
Shuai Han
HXHong Xu
Hong Xu
JZJinxian Zheng
Jinxian Zheng
JSJunhui Sun
Junhui Sun
XFXue Feng
Xue Feng
MGMichele A. Gatheridge
Michele A. Gatheridge
Carrier screening of Duchenne muscular dystrophy (DMD) has not been widely evaluated. To identify definite DMD female carriers prior to or in early pregnancy, we studied a large population of reproductive age females and provided informed reproductive options to DMD carriers. 37268 females were recruited from the Hangzhou Family Planning Publicity and Technology Guidance Station/Hangzhou Health Service Center for Children and Women, Hangzhou, China, between October 10, 2017, and December 16, 2018. CK activity was measured with follow‐up serum DMD genetic testing in subjects with hyperCKemia, defined as CK > 200 U/L. The calculated upper reference limit (97.5th percentile) of serum creatine kinase (CK) for females aged 20‐50 years in this study was near the reference limit recommended by the manufacturer (200 U/L), above which was defined as hyperCKemia. 427 females (1.2%) harbored initially elevated CK, among which 281 females (response rate of 65.8%) accepted CK retesting. DMD genetic testing was conducted on 62 subjects with sustained serum CK > 200 U/L and 16 females with a family history of DMD. Finally, 6 subjects were confirmed to be DMD definite carriers. The estimated DMD female carrier rate in this study was 1 : 4088 (adjusting for response rate), an underestimated rate, since only 50% to 70% of DMD female carriers manifest elevated serum CK, and carriers in this study may have been missed due to lack of follow‐up or inability to detect all DMD pathogenic variants by current genetic testing.

12 November 2015 in Journal of Human Genetics
Verified
Journal Article
Closed access
CWChen Weng
Chen Weng
JCJiao Chen
Jiao Chen
LSLi Sun
Li Sun
ZZZhong-Wei Zhou
Zhong-Wei Zhou
XFXue Feng
Xue Feng
MQMing Qi
Ming Qi

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SHShuai Han
Shuai Han
JSJunhui Sun
Junhui Sun
LYLiwei Yang
Liwei Yang
MQMing Qi
Ming Qi
Mutations in NDP and FZD4 have been closely related to a series of retinal diseases including familial exudative vitreoretinopathy (FEVR). Our study was designed to identify novel NDP and FZD4 mutations by whole exome sequencing (WES) in a cohort of patients with a definitive diagnosis of FEVR and explore the underlying molecular mechanism. During 2016, we investigated fifty nonconsanguineous families with affected individuals exhibiting FEVR phenotype and WES identified one recently reported mutation: NDP c.127C>A (p.H43N), and five novel mutations: NDP c.129_131del (p.44del), NDP c.320_353del (p.R107Pfs), NDP c.321delG (p.L108Cfs), NDP c.377G>T (p.C126F), and FZD4 c.314T>G (p.M105R) that cosegragated with the abnormal fundus vascular manifestations in six families. All the mutations were perceived to be pathogenic or likely pathogenic according to the standards and guidelines from the American College of Medical Genetics and Genomics (ACMG) and predicted to be deleterious by a series of bioinformatics analyses. We systematically performed functional analyses on the six mutations utilizing the Topflash reporter assay, where all NDP and FZD4 mutants revealed at least 50% loss of wild‐type activity. Immunoprecipitation finally demonstrated that the six mutations could degrade the Norrin‐Frizzled‐4 pair‐binding effect to varying degrees. Finally, our study underscores the correlation between the FEVR phenotype and genotype in NDP and FZD4, extending the mutation spectrum, allowing a reliable assessment of FEVR recurrence and improving genetic counseling. Further, our findings provide essential evidence for the follow‐up study of animal models and drug targets by Topflash assays and immunoprecipitation.

1 November 2021 in Fertility and Sterility
Verified
Journal Article
Closed access
WZWeijian Zhu
Weijian Zhu
LJLei Jiang
Lei Jiang
CPChengshuang Pan
Chengshuang Pan
JSJunhui Sun
Junhui Sun
XHXuefeng Huang
Xuefeng Huang
WNWuhua Ni
Wuhua Ni

14 February 2018 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
XFX. Feng
X. Feng
CWC. Weng
C. Weng
TWT. Wei
T. Wei
JSJ. Sun
J. Sun
FHF. Huang
F. Huang
MQMing Qi
Ming Qi

7 April 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XFXue Feng
Xue Feng
TWTianying Wei
Tianying Wei
JSJunhui Sun
Junhui Sun
YLYuqin Luo
Yuqin Luo
YHYanan Huo
Yanan Huo
YYYinghui Ye
Yinghui Ye
Leber congenital amaurosis (LCA) is a group of severe congenital retinal diseases. Variants in the guanylate cyclase 2D gene (GUCY2D), which encodes guanylate cyclase 1 (ROS-GC1), are associated with LCA1 and account for 6%–21% of all LCA cases. In this study, one family with LCA1 was recruited from China. A combination of next generation sequencing and Sanger sequencing was used to screen for disease-causing mutations. We found three novel mutations (c.139delC, p.Ala49Profs*36; c.835G>A, p.Asp279Asn and c.2783G>A, p.Gly928Glu) in the GUCY2D gene. Proband III-2 carries mutations c.139delC and c.2783G>A, which are inherited from the heterozygous mutation carriers, II-2 (c.139delC) and II-3 (c.2783G>A) that possess c.139delC and c.2783G>A. Additionally, II-8 carries heterozygous mutation c.835G>A. Sanger sequencing was used to confirm the presence of the three novel mutations in other family members. Mutation c.139delC results in a truncated protein. Mutations c.835G>A and c.2783G>A significantly reduce the catalytic activity of ROS-GC1. Our findings highlight the gene variants range of LCA. Moreover, HPLC-coupled tandem mass spectrometry (HPLC-MS/MS) was used to analyze the concentration of 3',5'-cyclic guanosine monophosphate (cGMP), suggesting that HPLC-MS/MS is an effective alternative method to evaluate the catalytic activity of wild-type and mutant ROS-GC1.